% 0期刊文章%詹姆斯Brenton %艾玛Woolbright %苏闽%仁Koshiya % Myla高盛% T女士儿科学科相比,减少了行走能力健康对照组(4818)% D J神经病学2020% % P V 94% 4818% N % X 15补充目的:评估的效用6分钟步行试验歧视行走能力的儿童相比,非MS女士控制。首页背景:小儿女士比健康的同龄人表现出低强度到高强度的体育运动,以连续个加速器。当个加速器主要决定步行行为,有一个明显缺乏知识在女士的孩子步行能力6分钟步行(6 mw)是一个时间步行测试评估行走易疲劳性和功能性行走能力。应用作为一种重要的测量结果在成人女士,这个测试在儿科人口女士的值是未知的。设计/方法:25儿科女士和50名健康受试者招募的控制。所有儿科学科女士遇到了2010年和2017年麦当劳标准研究人口统计学和人体测量信息收集女士访问包括年龄,性别,种族,体重/身高,腰围,吸烟史。所有受试者完成了6 mw评估使用一个标准化的协议。女士的研究对象接受扩大残疾状态量表(eds)评估。结果:儿科女士受试者的平均年龄17岁(范围:11到18门年)平均疾病持续时间2年。中位数eds女士科目分数为1.5。更大比例的受试者相比,超重/肥胖女士控制(60%比33%)。儿科学科女士走了明显更短的距离6分钟(6 mw)相对于控件(1868 + /−252和2061 + /−254英尺; p=0.004). In regression modeling, both MS disease and higher body mass index (BMI) influence performance on the 6MW, even after adjusting for level of neurologic disability (determined by EDSS).Conclusions: Pediatric MS subjects exhibit a slower performance on 6MW compared to non-MS peers, suggesting a lowered functional walking capacity independent of MS disability. Additionally, elevated BMI impacts 6MW performance, with slowest performance noted in those children who are obese and living with MS.Disclosure: Dr. Brenton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis.Dr. Woolbright has nothing to disclose. Dr. Min has nothing to disclose. Dr. Koshiya has nothing to disclose. Dr. Goldman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EMD Serono, Genzyme, Novartis Pharmaceuticals, Teva Neuroscience, RxMx, and Celgene. Dr. Goldman has received research support from MedDay, Novartis Pharmaceuticals, PCORI, and NMSS. %U

map